Press release
Deadline on May 24th coming up in Lawsuit for Investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX)
A Deadline is coming up on May 24, 2022, in the lawsuit for certain investors in Homology Medicines, Inc. (NASDAQ: FIXX).
Investors who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and there are strict and short deadlines running. Deadline: May 24, 2022. NASDAQ: FIXX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges on behalf of purchasers of Homology Medicines, Inc. (NASDAQ: FIXX) common shares between June 10, 2019 and February 18, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 10, 2019 and February 18, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that the Company had overstated HMI-102's efficacy and risk mitigation, that accordingly, it was unlikely that the Company would be able to commercialize HMI-102 in its present form, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on May 24th coming up in Lawsuit for Investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX) here
News-ID: 2627522 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Homology
Chapter 2: Medicine-Food Homology and FSMP | 2025 Nutrition Trends
Image: https://ecdn6.globalso.com/upload/p/2011/image_other/2025-10/ind-news-9.jpg
This article follows on from Chapter 1: 2025 FSMP Industry Trends , where we explored the global outlook, regulatory milestones, and policy drivers shaping the FSMP sector. In this second chapter, we look more closely at how the concept of medicine-food homology is influencing product innovation, clinical applications, and market opportunities.
From Treatment to FullCycle Health Management
Across Europe and Asia, the health industry is shifting from a focus on treating…
Chapter 2: Medicine-Food Homology and FSMP | 2025 Nutrition Trends
This article follows on from Chapter 1: 2025 FSMP Industry Trends, where we explored the global outlook, regulatory milestones, and policy drivers shaping the FSMP sector. In this second chapter, we look more closely at how the concept of medicine-food homology is influencing product innovation, clinical applications, and market opportunities.
From Treatment to Full‐Cycle Health Management
Across Europe and Asia, the health industry is shifting from a focus on treating disease to…
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
The Key Phenylketonuria Companies in the market include - PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharmaceuticals, and others.
The Phenylketonuria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Phenylketonuria pipeline products will significantly revolutionize the Phenylketonuria market dynamics.
DelveInsight's "Phenylketonuria Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as…
Hunter Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
The Hunter Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hunter Syndrome pipeline products will significantly revolutionize the Hunter Syndrome market dynamics.
DelveInsight's "Hunter Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United…
Investigation announced for Long-Term Investors in shares of Homology Medicines, …
An investigation was announced for long-term investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX) concerning potential breaches of fiduciary duties by certain directors of Homology Medicines, Inc..
Investors who are current long term investors in Homology Medicines, Inc. (NASDAQ: FIXX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX)
An investor, who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX), filed a lawsuit over alleged violations of Federal Securities Laws by Homology Medicines, Inc.
Investors who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2022. NASDAQ: FIXX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Bedford, MA based Homology…
